» Articles » PMID: 18236117

Systemic Therapy for Hepatocellular Carcinoma: Cytotoxic Chemotherapy, Targeted Therapy and Immunotherapy

Overview
Journal Ann Surg Oncol
Publisher Springer
Specialty Oncology
Date 2008 Feb 1
PMID 18236117
Citations 55
Authors
Affiliations
Soon will be listed here.
Abstract

Conventional cytotoxic chemotherapy has not provided clinical benefit or prolonged survival for patients with advanced HCC. This review summarizes the results of prospective clinical trials of several categories of systemic therapy, with emphasis on the more promising results from recent trials of biologically targeted therapeutic agents in HCC.

Citing Articles

BUB1 serves as a biomarker for poor prognosis in liver hepatocellular carcinoma.

Zhang L, Zhuge Y, Ni J BMC Immunol. 2025; 26(1):20.

PMID: 40069598 PMC: 11895216. DOI: 10.1186/s12865-025-00698-4.


Roles of clinical application of lenvatinib and its resistance mechanism in advanced hepatocellular carcinoma (Review).

Ye G, Ye M, Jin X Am J Cancer Res. 2024; 14(9):4113-4171.

PMID: 39417171 PMC: 11477829. DOI: 10.62347/UJVP4361.


[Status Quo and Development of Immunotherapy for Hepatocellular Carcinoma].

Wang T, Wang W Sichuan Da Xue Xue Bao Yi Xue Ban. 2023; 54(3):692-698.

PMID: 37248607 PMC: 10475433. DOI: 10.12182/20230560108.


Insights into an NEk2 inhibitory profile of nitidine chloride by molecular docking and biological evaluation.

Li D, Lu J, Zhang Q, Zhou Y, Li L, Zhu H BMC Chem. 2022; 16(1):75.

PMID: 36210464 PMC: 9549606. DOI: 10.1186/s13065-022-00870-6.


Rapidly Evolving Landscape and Future Horizons in Hepatocellular Carcinoma in the Era of Immuno-Oncology.

Kang S, Khalil L, El-Rayes B, Akce M Front Oncol. 2022; 12:821903.

PMID: 35433430 PMC: 9008732. DOI: 10.3389/fonc.2022.821903.